Inhaled pharmaceutical company Prosonix has hired Cécile Miles as its Chief Business Officer. She had been Commercial Director, Europe for the Arrow Group, part of Watson (now Actavis) since May 2011. Prior to Arrow, she had worked in various capacities at Ark Therapeutics, PLIVA, Ranbaxy, and Fisons.
Miles said, “I am very excited to be joining the Prosonix team at this crucial juncture in the company’s development. Prosonix is approaching some important development milestones in 2013 with the lead candidates in its respiratory medicine pipeline. In addition, the company is receiving great interest from third parties about the potential of its platform both to develop new medicines and to optimize those that are currently used in the treatment of respiratory diseases.”
Prosonix CEO David Hipkiss commented, “Cécile is a highly experienced business development professional and brings excellent complementary skills and understanding of the generics and specialty pharmaceutical markets to Prosonix. She will play a key role in driving Prosonix’ business development strategy over the coming years as we explore opportunities to capture the full potential value of our portfolio of directly substitutable inhaled generics and novel combination respiratory candidates. 2013 is expected to be an exciting year as we prepare to submit our application for marketing approval with European regulators for PSX1001, to initiate first clinical trials of PSX1002, and to advance the development of our novel PSX2000 combination candidates to address a range of respiratory diseases.”
Read the Prosonix press release.
